Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

acute myocardial infarction - myocardial revascularization - all type of patients  


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI

MERLIN (Sutton), 2004 - immediate systematic ballon angioplastyte vs no immediate angioplasty



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of myocardial revascularization
  • All clinical trials of Prehospital thrombolysis
    		•  

    GREAT study, 1994

    Treatments

    Studied treatment anistreplase by general practitioner
    Control treatment
    Treatments description
    Thrombolytic agent Anistreplase 
    Time from sympton onset to thrombolysis median 101/240 min; range 25-360/80-540 min 
    Provider GPs 

    Patients

    Inclusion criteria General practitioner’s clinical suspicion of AMI Symptoms of AMI present between 20 min and 4 h Transportation to ICU within 6 h from onset of symptoms Verbal consent given
    Exclusion criteria Thrombolysis <6 mo prior, surgery or major trauma <10 d prior, active gastrointestinal bleeding <6 mo prior, CVA or neurosurgery procedure <2 mo prior, intracranial aneurysm or neoplasm, history of thrombocytopenia, bleeding diasthesis or use of anticoagulants, pregnancy, heavy vaginal bleeding, diabetic proliferative retinopathy, BP >200/120 mm Hg, recent CPR, previous trial participant

    Method and design

    Randomized effectives 163 / 148 (studied vs. control)
    Blinding ND
    Follow-up duration ND
    Lost to follow-up ND
    Withdrawals (T1/T0) ND /


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    11 / 163
         17 / 148
         0,59 [0,28;1,21]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 11 / 163 (6,7%) 17 / 148 (11,5%) 0,59 [0,28;1,21]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 6,75% 11,49% -47,4‰


    Reference(s)

    Trials register # NA
    • Rawles J,. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT).. J Am Coll Cardiol 1994; 23:1-5
      Pubmed | Hubmed | Fulltext
    • . Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group.. BMJ 1992;305:548-53
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend